Chad vs Vanuatu: Hepatitis B surface antigen (HBsAg) prevalence
Chad
2.2%
in 2024
Vanuatu
1.8%
in 2024
Chad rank
11th
Vanuatu rank
13th
Hepatitis B surface antigen (HBsAg) prevalence over time
- Chad
- Vanuatu
How they compare
Chad currently reports 2.2% against 1.8% in Vanuatu, a difference of 0.4%.
That makes Chad's figure about 1.2 times Vanuatu's.
Across all 10 years both countries report, Chad has been ahead every year.
Chad ranks 11th and Vanuatu ranks 13th of 194 countries.
Chad has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Chad | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4.1% | 1.6% | 2.5% | Chad |
| 2020s | 3.0% | 1.7% | 1.3% | Chad |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Chad or Vanuatu?
- Chad, at 2.2% against 1.8% in Vanuatu as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Chad and Vanuatu?
- 0.4%, with Chad ahead.
- How many years of comparable data are there for Chad and Vanuatu?
- 10 years are reported by both, from 2015 to 2024.
- How do Chad and Vanuatu rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Chad ranks 11th and Vanuatu ranks 13th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.